Mather Group LLC. Buys 49 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Mather Group LLC. increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,641 shares of the pharmaceutical company’s stock after acquiring an additional 49 shares during the quarter. Mather Group LLC.’s holdings in Vertex Pharmaceuticals were worth $1,481,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of VRTX. Arlington Trust Co LLC increased its position in shares of Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 33 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $30,000. Baystate Wealth Management LLC lifted its holdings in shares of Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth about $25,000. Finally, NBC Securities Inc. bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of several recent research reports. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. JPMorgan Chase & Co. raised their target price on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Royal Bank of Canada boosted their price objective on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 6th. Truist Financial upped their target price on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, UBS Group reduced their price target on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $429.45.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $396.20 on Tuesday. The stock’s 50-day moving average is $411.08 and its 200-day moving average is $399.37. Vertex Pharmaceuticals Incorporated has a 1-year low of $320.01 and a 1-year high of $448.40. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. The stock has a market cap of $102.40 billion, a P/E ratio of 28.52, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.85 by $0.35. The firm had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the prior year, the company posted $3.33 EPS. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, Chairman Jeffrey M. Leiden sold 2,656 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, Chairman Jeffrey M. Leiden sold 2,656 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $419.51, for a total value of $1,114,218.56. Following the sale, the chairman now directly owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the transaction, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.